AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
The current price of ABBV is $219.68 USD — it has decreased by -2.52% in the past 24 hours. Watch Abbvie stock price performance more closely on the chart.
What is Abbvie stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Abbvie stocks are traded under the ticker ABBV.
Is Abbvie stock price growing?▼
ABBV stock has fallen by -3.42% compared to the previous week, the month change is a -5.11% fall, over the last year Abbvie has showed a +3.74% increase.
What is Abbvie market cap?▼
Today Abbvie has the market capitalization of 388.26B
When is the next Abbvie earnings date?▼
Abbvie is going to release the next earnings report on April 24, 2026.
What were Abbvie earnings last quarter?▼
ABBV earnings for the last quarter are 2.71 USD per share, whereas the estimation was 2.65 USD resulting in a +2.15% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Abbvie revenue for the last year?▼
Abbvie revenue for the last year amounts to 122.32B USD.
What is Abbvie net income for the last year?▼
ABBV net income for the last year is 8.45B USD.
Does Abbvie pay dividends?▼
Yes, ABBV dividends are paid quarterly. The last dividend per share was 1.73 USD. As of today, Dividend Yield (FWD)% is 3.15%.
How many employees does Abbvie have?▼
As of March 16, 2026, the company has 55,000 employees.